New drug combo challenges standard care in major lung cancer trial
NCT ID NCT07383116
Summary
This study aims to see if a new drug called HB0025, when given with standard chemotherapy, works better than the current standard immunotherapy (tislelizumab) plus chemotherapy for people with advanced non-squamous lung cancer. It will involve about 500 adults who have not yet received any treatment for their advanced cancer. The main goal is to see which treatment keeps the cancer from getting worse for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.